AntiRadical Therapeutics (ART) is developing novel drugs based on catalytic nitric oxide (CNO) linked to hemoglobin blood substitute aka SanFlow, for the treatment of cancer, chemobrain, heart attack, trauma, shock, Alzheimer’s disease, dementia, blood transfusion, sickle cell disease and Covid pandemic.

Nitric oxide (NO) is the key regulator of blood flow, oxygen delivery, antioxidant, anti-inflammatory and immune response activities in the central and peripheral organs on the cellular and vascular level across the blood brain barrier.

The efficacy of this drug activity has been published by the world specialists with funding from State, Federal and private investments.

ART will seek 17 years of global patent protection on compositions and methods of use of this CNO drug.

Confidential information on powerpoint presentation and the patent applications will be disclose under CDA with interested parties.